tetano
Editor, Senior Moderator
Biosaf Health
. 2023 Apr;5(2):89-100.
doi: 10.1016/j.bsheal.2023.02.002. Epub 2023 Mar 2. Rapid evaluation of heterologous chimeric RBD-dimer mRNA vaccine for currently-epidemic Omicron sub-variants as booster shot after inactivated vaccine
Qian Chen[SUP] 1 2 [/SUP], Pei Du[SUP] 2 [/SUP], Yuxuan Han[SUP] 2 3 [/SUP], Xuehui Ma[SUP] 2 [/SUP], Rong Zhang[SUP] 2 [/SUP], Xiaoyu Rong[SUP] 4 [/SUP], Xu Zhao[SUP] 2 3 [/SUP], Renyi Ma[SUP] 2 3 [/SUP], Huiting Yang[SUP] 2 3 [/SUP], Anqi Zheng[SUP] 2 3 [/SUP], Qingrui Huang[SUP] 2 [/SUP], Jinghua Yan[SUP] 1 2 3 [/SUP], Hui Wang[SUP] 5 [/SUP], Xin Zhao[SUP] 2 [/SUP], Lianpan Dai[SUP] 2 3 [/SUP], George F Gao[SUP] 2 3 [/SUP], Qihui Wang[SUP] 1 2 3 4 [/SUP]
Affiliations
With continuous mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the severe immune escape of Omicron sub-variants urges the development of next-generation broad-spectrum vaccines, especially as booster jabs after high-level vaccination coverage of inactivated vaccines in China and many other countries. Previously, we developed a coronavirus disease 2019 (COVID-19) protein subunit vaccine ZF2001® based on the tandem homo-prototype receptor-binding domain (RBD)-dimer of the SARS-CoV-2 spike protein. We upgraded the antigen into a hetero-chimeric prototype (PT)-Beta or Delta-BA.1 RBD-dimer to broaden the cross-protection efficacy and prove its efficiency with protein subunit and mRNA vaccine platforms. Herein, we further explored the hetero-chimeric RBD-dimer mRNA vaccines and evaluated their broad-spectrum activities as booster jabs following two doses of inactivated vaccine (IV) in mice. Our data demonstrated that the chimeric vaccines significantly boosted neutralizing antibody levels and specific T-cell responses against the variants, and PT-Beta was superior to Delta-BA.1 RBD as a booster in mice, shedding light on the antigen design for the next-generation COVID-19 vaccines.
Keywords: BA.5; Broad-spectrum; Omicron; RBD-dimer; SARS-CoV-2; mRNA Vaccine.
. 2023 Apr;5(2):89-100.
doi: 10.1016/j.bsheal.2023.02.002. Epub 2023 Mar 2. Rapid evaluation of heterologous chimeric RBD-dimer mRNA vaccine for currently-epidemic Omicron sub-variants as booster shot after inactivated vaccine
Qian Chen[SUP] 1 2 [/SUP], Pei Du[SUP] 2 [/SUP], Yuxuan Han[SUP] 2 3 [/SUP], Xuehui Ma[SUP] 2 [/SUP], Rong Zhang[SUP] 2 [/SUP], Xiaoyu Rong[SUP] 4 [/SUP], Xu Zhao[SUP] 2 3 [/SUP], Renyi Ma[SUP] 2 3 [/SUP], Huiting Yang[SUP] 2 3 [/SUP], Anqi Zheng[SUP] 2 3 [/SUP], Qingrui Huang[SUP] 2 [/SUP], Jinghua Yan[SUP] 1 2 3 [/SUP], Hui Wang[SUP] 5 [/SUP], Xin Zhao[SUP] 2 [/SUP], Lianpan Dai[SUP] 2 3 [/SUP], George F Gao[SUP] 2 3 [/SUP], Qihui Wang[SUP] 1 2 3 4 [/SUP]
Affiliations
- PMID: 37123450
- PMCID: PMC9979697
- DOI: 10.1016/j.bsheal.2023.02.002
With continuous mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the severe immune escape of Omicron sub-variants urges the development of next-generation broad-spectrum vaccines, especially as booster jabs after high-level vaccination coverage of inactivated vaccines in China and many other countries. Previously, we developed a coronavirus disease 2019 (COVID-19) protein subunit vaccine ZF2001® based on the tandem homo-prototype receptor-binding domain (RBD)-dimer of the SARS-CoV-2 spike protein. We upgraded the antigen into a hetero-chimeric prototype (PT)-Beta or Delta-BA.1 RBD-dimer to broaden the cross-protection efficacy and prove its efficiency with protein subunit and mRNA vaccine platforms. Herein, we further explored the hetero-chimeric RBD-dimer mRNA vaccines and evaluated their broad-spectrum activities as booster jabs following two doses of inactivated vaccine (IV) in mice. Our data demonstrated that the chimeric vaccines significantly boosted neutralizing antibody levels and specific T-cell responses against the variants, and PT-Beta was superior to Delta-BA.1 RBD as a booster in mice, shedding light on the antigen design for the next-generation COVID-19 vaccines.
Keywords: BA.5; Broad-spectrum; Omicron; RBD-dimer; SARS-CoV-2; mRNA Vaccine.